Title:Design, Synthesis, Molecular Docking Study and Anti-Hepatocellular Carcinoma Evaluation of New Bis-Triazolothiadiazines
VOLUME: 20 ISSUE: 9
Author(s):Sobhi M. Gomha, Zeinab A. Muhammad*, Elham Ezz El-Arab, Amira M. Elmetwally, Abdelaziz A. El-Sayed and Islam K. Matar
Affiliation:Department of Chemistry, Faculty of Science, Islamic University in Almadinah Almonawara, Almadinah Almonawara, 42351, Organic Chemistry Department, National Organization for Drug Control and Research (NODCAR), Giza 12311, Organic Chemistry Department, National Organization for Drug Control and Research (NODCAR), Giza 12311, Organic Chemistry Department, National Organization for Drug Control and Research (NODCAR), Giza 12311, Department of Chemistry, Faculty of Science, Islamic University in Almadinah Almonawara, Almadinah Almonawara, 42351, Majecules LLC., Cairo 11361
Keywords:1, 4-dihydropyridines, triazolo-thiadiazines, hydrazonoyl halides, molecular docking, antitumor activities, in vitro.
Abstract:
Objective: The reaction of bis(4-amino-4H-1,2,4-triazole-3-thiol) with hydrazonoyl halides
and α-halo-ketones gave a new series of bis-1,2,4-triazolo[3,4-b]thiadiazine derivatives.
Methods: The structure of the new products was established on the basis of their elemental and spectral
data (mass, 1H NMR, 13C NMR and IR) and an alternate method.
Results: Several of the synthesized products were subjected to in vitro anticancer screening against
human hepatocellular carcinoma (HepG-2) and the results showed that compounds 16, 14 and 12 have
promising activities (IC50 value of 24.8±9.1, 28.3±0.5, and 31±2.9μM, respectively) compared with
Harmine reference drug (IC50 value of 22.4±1.11 μM).
Conclusion: Moreover, molecular docking studies were performed to analyze the binding modes of the
discovered hits into the active site of DYRK1A using iGEMDOCK.